| Literature DB >> 26405287 |
Louise Fleming1, Clare Murray2, Aruna T Bansal3, Simone Hashimoto4, Hans Bisgaard5, Andrew Bush6, Urs Frey7, Gunilla Hedlin8, Florian Singer9, Wim M van Aalderen10, Nadja H Vissing5, Zaraquiza Zolkipli11, Anna Selby11, Stephen Fowler12, Dominick Shaw13, Kian Fan Chung1, Ana R Sousa14, Scott Wagers15, Julie Corfield16, Ioannis Pandis17, Anthony Rowe18, Elena Formaggio19, Peter J Sterk4, Graham Roberts20.
Abstract
U-BIOPRED aims to characterise paediatric and adult severe asthma using conventional and innovative systems biology approaches. A total of 99 school-age children with severe asthma and 81 preschoolers with severe wheeze were compared with 49 school-age children with mild/moderate asthma and 53 preschoolers with mild/moderate wheeze in a cross-sectional study. Despite high-dose treatment, the severe cohorts had more severe exacerbations compared with the mild/moderate ones (annual medians: school-aged 3.0 versus 1.1, preschool 3.9 versus 1.8; p<0.001). Exhaled tobacco exposure was common in the severe wheeze cohort. Almost all participants in each cohort were atopic and had a normal body mass index. Asthma-related quality of life, as assessed by the Paediatric Asthma Quality of Life Questionnaire (PAQLQ) and the Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ), was worse in the severe cohorts (mean±se school-age PAQLQ: 4.77±0.15 versus 5.80±0.19; preschool PACQLQ: 4.27±0.18 versus 6.04±0.18; both p≤0.001); however, mild/moderate cohorts also had significant morbidity. Impaired quality of life was associated with poor control and airway obstruction. Otherwise, the severe and mild/moderate cohorts were clinically very similar. Children with severe preschool wheeze or severe asthma are usually atopic and have impaired quality of life that is associated with poor control and airflow limitation: a very different phenotype from adult severe asthma. In-depth phenotyping of these children, integrating clinical data with high-dimensional biomarkers, may help to improve and tailor their clinical management.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26405287 DOI: 10.1183/13993003.00780-2015
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671